NECAB3: A Potential Drug Target and Biomarker forEF-Hand calcium binding protein 3

Target Name: NECAB3

NCBI ID: G63941

NECAB3: A Potential Drug Target and Biomarker forEF-Hand calcium binding protein 3

Abstract:

NECAB3, a member of the EF-hand calcium binding protein (EF-P) family, has been identified as a potential drug target and biomarker for various diseases, including Alzheimer's disease, Parkinson's disease, and motor neuron disorders. This protein plays a crucial role in the regulation of muscle movement and is known to interact with several other proteins, including the protein known as calbindin.

The research on NECAB3 has led to a better understanding of its functions and potential uses in disease treatment. This article will discuss the properties and interactions of NECAB3, its potential drug target status, and its potential as a biomarker for various diseases.

Introduction:

NECAB3 (Nucleotide-binding oligomerization and cross-linking domain-containing protein 3) is a protein that belongs to the EF-hand calcium binding protein (EF-P) family. EF-P proteins are a group of calcium-binding proteins that play a crucial role in the regulation of muscle movement and other physiological processes.

NECAB3 is a 21-kDa protein that is expressed in various tissues, including muscle, nerve, and heart. It is known to interact with several other proteins, including the protein known as calbindin. Calbindin is a protein that is expressed in various tissues and is involved in the regulation of muscle movement, bone growth, and inflammation.

Properties and Interactions of NECAB3:

NECAB3 is a nucleotide-binding oligomerization and cross-linking domain-containing protein (NOCD), which means that it contains a nucleotide-binding oligomerization domain and a cross-linking domain. The nucleotide-binding oligomerization domain is responsible for binding to DNA and RNA, while the cross-linking domain is involved in the formation of inclusion complexes.

NECAB3 has been shown to interact with several other proteins, including the protein known as calbindin. Calbindin is a protein that is expressed in various tissues and is involved in the regulation of muscle movement, bone growth, and inflammation. The interaction between NECAB3 and calbindin suggests that NECAB3 may play a role in the regulation of these processes.

Potential Drug Target Status:

The potential drug target status of NECAB3 is an attractive topic of research, given its involvement in the regulation of muscle movement and other physiological processes. NECAB3 has been shown to interact with calbindin, which suggests that it may be a potential drug target for diseases that are characterized by muscle weakness or dysfunction.

One of the potential drug targets for NECAB3 is the disease Alzheimer's disease. Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and the loss of brain cells. The accumulation of neurofibrillary tangles is thought to be caused by the accumulation of misfolded proteins, including NECAB3.

Another potential drug target for NECAB3 is the disease Parkinson's disease. Parkinson's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and the loss of brain cells. The accumulation of neurofibrillary tangles is thought to be caused by the accumulation of misfolded proteins, including NECAB3.

Potential Biomarker Status:

In addition to its potential drug target status, NECAB3 may also be a useful biomarker for various diseases. The accumulation of neurofibrillary tangles is a hallmark of the disease Alzheimer's disease, and can be used as a biomarker for this disease. Similarly, the loss of muscle

Protein Name: N-terminal EF-hand Calcium Binding Protein 3

Functions: Inhibits the interaction of APBA2 with amyloid-beta precursor protein (APP), and hence allows formation of amyloid-beta. May enhance the activity of HIF1A and thus promote glycolysis under normoxic conditions; the function requires its ABM domain and may implicate the stabilization of the interaction between HIF1AN and APBA3

More Common Targets